Women’s Brain Health Initiative’s Mind Over Matter magazine’s latest issue features interviews with CCNA’s Drs. Gillian Einstein and M. Natasha Rajah discussing recent meetings they led addressing sex and diversity gaps in Alzheimer’s disease research. Click here to read...
CCNA is thrilled that one of our senior dementia scientists, Dr. Kenneth Rockwood (Dalhousie University) is receiving the recognition of the Order of Canada for his major research contributions. Dr. Rockwood has been a critical member of CCNA since its inception, and we take g...
Thanks to a $20.6M investment from CIHR, the Canadian Consortium on Neurodegeneration in Aging is embarking on its third phase to continue important and meaningful research. The nominated principal investigator of the grant is CCNA’s Scientific Director, Dr. Howard Chert...
This Alzheimer’s Awareness Month, CCNA trainee, Laura Fitzgibbon-Collins, will lead an online story time for kids in collaboration with Let’s Talk Science (January 30th, 1 pm ET).
CCNA Team 12 members have published the first CCNA Randomized Clinical Trial showing positive effects of multidomain interventions for improving cognition in mild cognitive impairment. Read the paper here. Read the media release here.
The Driving and Dementia Roadmap (DDR), a free online Canadian resource developed by CCNA’s Team 16 researchers at Baycrest and Sunnybrook Health Sciences has recently been included as a dementia resource on a World Health Organization’s (WHO) Global Dementia Observatory...
CCNA congratulates Dr. Sandra Black for receiving the 2022 Bill Thies Award for Distinguished Service to the International Society to Advance Alzheimer’s Research and Treatment (ISTAART).
On January 19, 2022 (1-2 pm ET) we will host Dr. Naila Kuhlmann for a webinar on arts-based knowledge translation. The webinar will discuss the process of creating the Piece of Mind performance. It will address the questions of what is art-based knowledge translation, and how ...
Canada’s dementia experts urge caution in the review of aducanumab, a medication for Alzheimer’s disease Researchers and clinicians from six leading Canadian organizations working in the dementia research and care field, came to the conclusion that aducanumab – the trea...
On July 21, 2021 (13:00-14:15 ET), the Ethics, Legal and Social Implications Cross-cutting program invites you to join for the next Improbable Encounter, a CCNA Talking Brains Webinar. What are biomarkers and what do they represent for people with dementia? How are biomarkers ...